Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsXPAR:ABLD 49 Return-on-Tangible-Asset is 15.20% as of Dec. 2025, which is 887% above its 10-year median of 1.54. GuruFocus rates XPAR:ABLD with a GF Score™ of 49/100 and a GF Value™ of €7.92 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 680 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 83.09% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ABL Diagnostics's annualizedNet Income for the quarter that ended in Dec. 2025 was €1.40 Mil. ABL Diagnostics's average total tangible assets for the quarter that ended in Dec. 2025 was €9.18 Mil. Therefore, ABL Diagnostics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 15.20%.
The historical rank and industry rank for ABL Diagnostics's Return-on-Tangible-Asset or its related term are showing as below:
XPAR:ABLD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.07 Med: 1.54 Max: 21.42
Current: 10.78
During the past 13 years, ABL Diagnostics's highest Return-on-Tangible-Asset was 21.42%. The lowest was -7.07%. And the median was 1.54%.
XPAR:ABLD's Return-on-Tangible-Asset is ranked better than 83.09% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 2.465
vs XPAR:ABLD: 10.78
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ABL Diagnostics Return-on-Tangible-Asset Related Terms
ABL Diagnostics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, ABL Diagnostics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 15.20% mean?
ABL Diagnostics (XPAR:ABLD) has a Return-on-Tangible-Asset of 15.20% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ABL Diagnostics and its competitors. This is 887% above median its historical median of 1.54. According to the industry distribution chart, ABL Diagnostics ranks #115 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 16.9%.
Is ABL Diagnostics' Return-on-Tangible-Asset too high?
ABL Diagnostics' current Return-on-Tangible-Asset of 15.20% is 887% above median its 10-year median of 1.54. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.47. ABL Diagnostics' value of 15.20% is 516.6% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #115 out of 680 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #115 out of 680 companies for Return-on-Tangible-Asset. This places ABL Diagnostics in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.47. ABL Diagnostics' value of 15.20% is 516.6% above this benchmark. While the company's 10-year median is 1.54 vs. the industry median of 2.47, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.47, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Return-on-Tangible-Asset of 15.20% is 516.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Return-on-Tangible-Asset is 15.20%, which is 887% above median its own 10-year median of 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.92, compared to a current price of €2.50 — trading 68.4% below its estimated fair value. The current Return-on-Tangible-Asset is 15.20%, which is 887% above median its 10-year median of 1.54 and 516.6% above the Healthcare Providers & Services industry median of 2.47. ABL Diagnostics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Return-on-Tangible-Asset is 15.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.50 is trading 68.4% below its estimated GF Value™ of €7.92.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Return-on-Tangible-Asset: 15.20% (887% above median its 10-year median of 1.54)
GF Value™: €7.92 vs. price of €2.50 (68.4% below fair value)
Industry Position: 516.6% above the Healthcare Providers & Services median (#115 of 680)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
49GF Score
Get the complete analysis for XPAR:ABLD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
